Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


1st U.S. Biosimilar Arrives: Zarxio Launches; Legal Saga Ongoing

This article was originally published in Scrip

Executive Summary

The day after Amgen was dealt another blow at the U.S. Court of Appeals for the Federal Circuit in the company's failed attempt to keep Novartis unit Sandoz from launching its biosimilar Zarxio (filgrastim-sndz), the latter firm moved forward with putting the medicine on the U.S. market – the first biologic copycat available to Americans.


Related Content

Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition
Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back
Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales
Innovators Employ Labyrinthine Defenses To Fend Off Biosimilars
Sandoz's Biosimilar Rejection Ups Risks, But Won't Kill Market
Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?
Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts